Hollyfrontier (HFC) Stake Maintained by Sumitomo Mitsui Trust Holdings Inc; As Amag Pharmaceuticals (AMAG) Shares Rose, Falcon Point Capital Has Increased Position by $676,760

June 18, 2018 - By reb123z

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Logo

Falcon Point Capital Llc increased its stake in Amag Pharmaceuticals Inc. (AMAG) by 4.94% based on its latest 2018Q1 regulatory filing with the SEC. Falcon Point Capital Llc bought 33,838 shares as the company’s stock rose 19.10% while stock markets declined. The institutional investor held 719,075 shares of the health care company at the end of 2018Q1, valued at $14.49 million, up from 685,237 at the end of the previous reported quarter. Falcon Point Capital Llc who had been investing in Amag Pharmaceuticals Inc. for a number of months, seems to be bullish on the $789.51 million market cap company. The stock decreased 3.36% or $0.8 during the last trading session, reaching $23. About 895,906 shares traded or 14.13% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 30.22% since June 18, 2017 and is uptrending. It has outperformed by 17.65% the S&P500. Some Historical AMAG News: 03/05/2018 – AMAG Pharmaceuticals 1Q Loss/Shr $1.59; 26/03/2018 – Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women; 10/04/2018 – Amag Pharma at Deutsche Bank Health Care Conference May 8; 03/05/2018 – AMAG PHARMACEUTICALS – SEES 2018 NON-GAAP ADJUSTED EBITDA $120 MLN – $140 MLN; 23/03/2018 – AMAG Pharmaceuticals: If Sandoz Receives FDA Approval By a Certain Date, Sandoz May Launch its Generic Version of Feraheme on July 15, 2021; 23/03/2018 – AMAG PHARMACEUTICALS – IF SANDOZ RECEIVES FDA APPROVAL BY A CERTAIN DATE, SANDOZ MAY LAUNCH GENERIC VERSION OF FERAHEME ON JULY 15, 2021, OR EARLIER; 03/05/2018 – AMAG Pharmaceuticals Raises 2018 View To Rev $540M-$580M; 26/03/2018 – AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatmen; 23/03/2018 – AMAG PHARMACEUTICALS – SETTLEMENT DISMISSES & RESOLVES PATENT LITIGATION RELATED TO CO’S FERAHEME, 30 MG/ML, 17 ML SINGLE DOSE VIALS FOR INTRAVENOUS USE; 09/05/2018 – Amag Pharma Short-Interest Ratio Rises 57% to 18 Days




Sumitomo Mitsui Trust Holdings Inc increased its stake in Hollyfrontier Corp (HFC) by 9.73% based on its latest 2018Q1 regulatory filing with the SEC. Sumitomo Mitsui Trust Holdings Inc bought 48,159 shares as the company’s stock rose 61.32% while stock markets declined. The institutional investor held 542,940 shares of the integrated oil company at the end of 2018Q1, valued at $26.53M, up from 494,781 at the end of the previous reported quarter. Sumitomo Mitsui Trust Holdings Inc who had been investing in Hollyfrontier Corp for a number of months, seems to be bullish on the $12.99B market cap company. The stock increased 2.63% or $1.9 during the last trading session, reaching $74.2. About 4.20M shares traded or 29.68% up from the average. HollyFrontier Corporation (NYSE:HFC) has risen 184.95% since June 18, 2017 and is uptrending. It has outperformed by 172.38% the S&P500. Some Historical HFC News: 23/03/2018 – HollyFrontier: Utah Refinery’s Ability to Receive Crude Oil Deliveries Has Been Affected; 02/05/2018 – HollyFrontier Corp. 1Q EBITDA $487.6M; 03/04/2018 – HollyFrontier Corporation First Quarter 2018 Earnings Release and Conference Webcast; 02/05/2018 – HOLLYFRONTIER HASN’T HEARD STATUS OF WOODS CROSS RFS WAIVER; 20/04/2018 – DJ HollyFrontier Corporation, Inst Holders, 1Q 2018 (HFC); 02/05/2018 – HollyFrontier 1Q Rev $4.13B; 29/05/2018 – HollyFrontier Corp Statement on the Passing of Former Chmn and CEO, Lamar Norsworthy; 23/03/2018 – HollyFrontier: In the Process of Determining the Scope of the Damage Resulting From the Fire; 26/03/2018 – HOLLYFRONTIER SEES 2018 REFINING & MARKETING CAPEX OF $375 MLN TO $425 MLN – SEC FILING; 31/05/2018 – EXCLUSIVE-U.S. EPA AWARDS SINCLAIR OIL, HOLLYFRONTIER MILLIONS OF DOLLARS IN BIOFUELS CREDITS FOR WAIVER DENIALS -SOURCES, FILINGS

Falcon Point Capital Llc, which manages about $364.50 million and $500.20M US Long portfolio, decreased its stake in Prestige Brands Holdings Inc. (NYSE:PBH) by 72,302 shares to 241,553 shares, valued at $8.15M in 2018Q1, according to the filing. It also reduced its holding in Fireeye Inc. (NASDAQ:FEYE) by 207,839 shares in the quarter, leaving it with 1.17 million shares, and cut its stake in Apogee Enterprises Inc. (NASDAQ:APOG).

More notable recent AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 21, 2018, also Benzinga.com with their article: “30 Stocks Moving In Friday’s Mid-Day Session” published on June 15, 2018, Streetinsider.com published: “Pre-Open Stock Movers 06/15: (VSTM) (TXMD) (GLUU) Higher; (AFMD) (GBT) (GNK) Lower (more…)” on June 15, 2018. More interesting news about AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) were released by: Globenewswire.com and their article: “Analysis: Positioning to Benefit within The Stars Group, AMAG Pharmaceuticals, ResMed, WestRock, Briggs & Stratton …” published on June 18, 2018 as well as Nasdaq.com‘s news article titled: “AMAG Pharmaceuticals to Present at Upcoming Investor Conference” with publication date: May 29, 2018.

Among 14 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 3 have Buy rating, 1 Sell and 10 Hold. Therefore 21% are positive. AMAG Pharmaceuticals had 51 analyst reports since August 18, 2015 according to SRatingsIntel. As per Wednesday, February 14, the company rating was maintained by Cantor Fitzgerald. The firm earned “Buy” rating on Tuesday, June 6 by Jefferies. The company was initiated on Friday, September 8 by Morgan Stanley. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Buy” rating by Jefferies on Tuesday, August 18. The company was downgraded on Wednesday, January 11 by Needham. As per Thursday, February 15, the company rating was upgraded by Janney Capital. Cantor Fitzgerald maintained the stock with “Hold” rating in Monday, June 4 report. The firm earned “Neutral” rating on Friday, June 15 by Janney Capital. The firm has “Market Perform” rating given on Wednesday, May 4 by Raymond James. The firm has “Equal-Weight” rating given on Thursday, January 21 by Barclays Capital.

Since February 23, 2018, it had 0 insider purchases, and 2 sales for $516,016 activity. Vittiglio Joseph had sold 770 shares worth $16,016.

Investors sentiment decreased to 0.84 in Q1 2018. Its down 0.06, from 0.9 in 2017Q4. It worsened, as 27 investors sold AMAG shares while 55 reduced holdings. 32 funds opened positions while 37 raised stakes. 37.48 million shares or 0.65% less from 37.72 million shares in 2017Q4 were reported. Renaissance Technology Ltd Liability Company owns 1.54 million shares for 0.03% of their portfolio. First Trust Advsrs Limited Partnership reported 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Prudential Financial Incorporated reported 0% stake. State Street accumulated 2.67M shares or 0% of the stock. New York-based Alliancebernstein LP has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Balyasny Asset Mngmt Ltd Limited Liability Company, a Illinois-based fund reported 14,882 shares. Canada Pension Plan Investment Board holds 0% or 400 shares in its portfolio. Panagora Asset Mgmt owns 362,252 shares. Teachers Retirement Sys Of The State Of Kentucky holds 0% or 8,631 shares in its portfolio. Hourglass Capital Ltd Liability Com reported 0.56% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Metropolitan Life Ins Co has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Tudor Et Al reported 12,344 shares stake. Swiss Bancorporation holds 63,457 shares. Dupont Cap Mngmt invested 0.03% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Lpl Finance Ltd Co holds 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 34,343 shares.

Since May 4, 2018, it had 0 insider purchases, and 16 insider sales for $19.16 million activity. The insider Gann John W Jr sold 8,500 shares worth $564,315. Another trade for 51,771 shares valued at $4.18 million was made by Damiris George John on Monday, June 4. McWatters Denise Clark had sold 15,821 shares worth $1.05M. $566,790 worth of HollyFrontier Corporation (NYSE:HFC) shares were sold by Voliva Richard Lawrence III. BECH DOUGLAS Y sold $995,011 worth of stock or 15,000 shares. Shares for $953,550 were sold by ECHOLS LELDON E.

Investors sentiment decreased to 0.92 in Q1 2018. Its down 0.27, from 1.19 in 2017Q4. It dropped, as 51 investors sold HFC shares while 133 reduced holdings. 55 funds opened positions while 115 raised stakes. 143.57 million shares or 0.38% less from 144.13 million shares in 2017Q4 were reported. Schroder Investment Mngmt Group, Maine-based fund reported 2.02 million shares. Shelton Cap Mgmt has 12,421 shares for 0.04% of their portfolio. Manufacturers Life The has 285,441 shares. Balyasny Asset Mngmt owns 38,430 shares for 0.01% of their portfolio. The Australia-based Amp Capital Ltd has invested 0.05% in HollyFrontier Corporation (NYSE:HFC). Lpl Finance Ltd Llc holds 20,840 shares. Ftb Advsrs stated it has 0% in HollyFrontier Corporation (NYSE:HFC). Piedmont Inv Lc stated it has 23,461 shares or 0.03% of all its holdings. 47,200 are owned by Deroy And Devereaux Private Counsel Inc. Suntrust Banks Inc reported 57,246 shares or 0.02% of all its holdings. Dupont Mngmt invested 0.03% in HollyFrontier Corporation (NYSE:HFC). Jefferies Group Limited Liability Corporation has invested 0% in HollyFrontier Corporation (NYSE:HFC). Vanguard Grp holds 0.04% of its portfolio in HollyFrontier Corporation (NYSE:HFC) for 18.84M shares. Lingohr Partner Asset Mgmt Gmbh accumulated 19,100 shares. Bnp Paribas Asset Management Hldg Sa invested in 30,052 shares.

Another recent and important HollyFrontier Corporation (NYSE:HFC) news was published by Seekingalpha.com which published an article titled: “HollyFrontier: A RIN Diesel Opportunity?” on June 06, 2018.

Among 21 analysts covering HollyFrontier (NYSE:HFC), 8 have Buy rating, 5 Sell and 8 Hold. Therefore 38% are positive. HollyFrontier had 84 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was upgraded by Howard Weil to “Outperform” on Wednesday, May 18. The stock of HollyFrontier Corporation (NYSE:HFC) earned “Buy” rating by Deutsche Bank on Friday, December 18. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, November 1. The firm has “Hold” rating given on Thursday, July 13 by Cowen & Co. Oppenheimer maintained HollyFrontier Corporation (NYSE:HFC) on Saturday, September 5 with “Outperform” rating. RBC Capital Markets maintained HollyFrontier Corporation (NYSE:HFC) on Monday, November 6 with “Buy” rating. The stock has “Buy” rating by RBC Capital Markets on Tuesday, January 30. The rating was maintained by Piper Jaffray with “Hold” on Monday, April 23. The stock has “Buy” rating by RBC Capital Markets on Friday, April 13. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, October 18.

Sumitomo Mitsui Trust Holdings Inc, which manages about $77.76 billion US Long portfolio, decreased its stake in Lowe’s Cos Inc (NYSE:LOW) by 8,305 shares to 2.44M shares, valued at $214.53M in 2018Q1, according to the filing. It also reduced its holding in Spdr Djia Trust (DIA) by 12,000 shares in the quarter, leaving it with 8,000 shares, and cut its stake in Ishares Msci India Etf (INDA).

HollyFrontier Corporation (NYSE:HFC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.